Your session is about to expire
← Back to Search
Nerofe for Acute Myeloid Leukemia
Study Summary
This trial is testing a new drug, NEROFE, to see if it is safe and effective in treating patients with MDS or AML. NEROFE will be given intravenously three times per week, and the dosage will be based on the patient's weight.
- Acute Myeloid Leukemia
- Myelodysplastic Syndrome
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Is there still an opportunity to register for this investigation?
"Affirmative. According to information stored on clinicaltrials.gov, this medical research is actively seeking participants with the original post date of June 18th 2020 and most recent edit made on July 21st 2022. The trial has a goal of recruiting 18 patients from 1 site."
What is the participant capacity for this clinical research?
"Affirmative. The clinicaltrials.gov database conveys that this trial is presently recruiting volunteers, with the initial posting date being June 18th 2020 and the last update occurring on July 21st 2022. Researchers seek to recruit 18 participants from one medical facility."
Is this experiential research pioneering a new approach?
"Presently, only one active clinical trial for Nerofe is running in 1 city and country. Initially run by Immune System Key Ltd in 2020, this Phase 1 drug approval process enrolled 18 patients and completed successfully. Since then, no other trials have been conducted."
Are there any other trials that have been conducted utilizing Nerofe?
"Presently, there is one operational clinical investigation for Nerofe with no Phase 3 trials. This research has a hub in Miami, Florida and an additional location conducting experiments."
Has Nerofe been accorded official authorization by the FDA?
"With limited evidence to suggest its efficacy and safety, Nerofe has been assigned a rating of 1 by our team at Power."
Share this study with friends
Copy Link
Messenger